ORCHPHARMA Share Price Target 2040

CAGR-based price projection for Orchid Pharma Limited (ORCHPHARMA) targeting 2040, derived from official NSE exchange closing prices.

Bear Case (30.9% CAGR)
Rs 42,836
2040 Target
Base Case (77.2% CAGR)
Rs 2,978,698
2040 Target
Bull Case (278.2% CAGR)
Rs 121,195,272,219
2040 Target

Current Market Snapshot

CMP: Rs 990.00
52W High: Rs 1,107.20
52W Low: Rs 545.30
1Y CAGR: 214.0%
3Y CAGR: 77.2%

Year-by-Year Price Projection

YearBear CaseBase CaseBull Case
2027 Rs 1,296 Rs 1,754 Rs 3,744
2028 Rs 1,696 Rs 3,108 Rs 14,159
2029 Rs 2,219 Rs 5,508 Rs 53,548
2030 Rs 2,905 Rs 9,760 Rs 202,511
2031 Rs 3,802 Rs 17,295 Rs 765,867
2032 Rs 4,976 Rs 30,646 Rs 2,896,389
2033 Rs 6,512 Rs 54,304 Rs 10,953,690
2034 Rs 8,523 Rs 96,225 Rs 41,425,146
2035 Rs 11,155 Rs 170,508 Rs 156,663,436
2036 Rs 14,599 Rs 302,135 Rs 592,476,671
2037 Rs 19,107 Rs 535,374 Rs 2,240,654,321
2038 Rs 25,007 Rs 948,666 Rs 8,473,805,015
2039 Rs 32,729 Rs 1,681,009 Rs 32,046,608,331
2040 Rs 42,836 Rs 2,978,698 Rs 121,195,272,219

Other ORCHPHARMA Price Targets

2025 2026 2027 2028 2030 2035 2050

Frequently Asked Questions

What is the ORCHPHARMA share price target for 2040?

Based on historical growth analysis, the ORCHPHARMA share price target for 2040 ranges from Rs 42,836 (conservative) to Rs 2,978,698 (base case) to Rs 121,195,272,219 (optimistic). These projections are based on trailing CAGR and should not be treated as guaranteed outcomes.

What is the current share price of ORCHPHARMA?

The current market price of ORCHPHARMA (Orchid Pharma Limited) is Rs 990.00. The 52-week high is Rs 1,107.20 and 52-week low is Rs 545.30.

Is ORCHPHARMA a good stock to buy for the long term?

Long-term investment decisions depend on individual risk tolerance, financial goals, and portfolio diversification. Examine the company's fundamentals, debt-to-equity ratio, promoter holding, and competitive positioning within its sector. BrokerLens provides data-driven analysis; consult a SEBI-registered financial advisor before investing.

What methodology does BrokerLens use for ORCHPHARMA price targets?

BrokerLens computes price targets using historical Compound Annual Growth Rate (CAGR) derived from official NSE closing prices. Three scenarios are modeled: Bear (conservative at 30.9% CAGR), Base (77.2% CAGR), and Bull (optimistic at 278.2% CAGR). These are statistical projections, not guaranteed forecasts.

Disclaimer: Share price targets on BrokerLens are statistical CAGR projections based on historical NSE closing prices. They are NOT guaranteed outcomes, investment advice, or analyst recommendations. Past performance does not guarantee future results. Consult a SEBI-registered investment advisor before making investment decisions. Mutual fund and equity investments are subject to market risks.